Physician profile
Andromeda Raindance
NPI 1033557640
$495.05
in general payments reported to CMS, 2019-2025
14 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $123.76 | 2025 | Apretude, Rukobia |
| Exact Sciences Corporation | $75.50 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $73.01 | 2025 | Pifeltro, Delstrigo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $30.74 | 2025 | |
| Lilly USA, LLC | $28.98 | 2025 | Jardiance |
| Organon LLC | $27.03 | 2025 | |
| Pfizer INC. | $20.92 | 2025 | |
| Glaxosmithkline, LLC. | $20.00 | 2025 | Trelegy Ellipta |
| Tandem Diabetes Care, INC. | $18.21 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $17.76 | 2025 | Hyqvia |
| Esperion Therapeutics, INC. | $16.79 | 2025 | Nexletol |
| Inspire Medical Systems, INC. | $14.76 | 2025 | Inspire |
| Novo Nordisk INC | $13.98 | 2025 | Wegovy |
| Verona Pharma, INC. | $13.61 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andromeda Raindance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.